Workflow
Lilly(LLY)
icon
Search documents
FDA前疫苗部门负责人已加盟礼来公司
Xin Lang Cai Jing· 2025-10-07 19:39
美股周二尾盘,礼来公司(LLY)股价小幅上扬,此前有报道称,美国食品药品监督管理局(FDA)前疫苗 部门负责人彼得·马克斯(Peter Marks)已加盟礼来公司。 来源:环球市场播报 ...
Former FDA vaccine chief Peter Marks joins Eli Lilly, STAT reports
Reuters· 2025-10-07 19:16
Peter Marks, the former top vaccine regulator at the U.S. Food and Drug Administration, has joined Eli Lilly , STAT News reported on Tuesday. ...
Looking At Eli Lilly's Recent Unusual Options Activity - Eli Lilly (NYSE:LLY)
Benzinga· 2025-10-07 16:01
Investors with a lot of money to spend have taken a bullish stance on Eli Lilly (NYSE:LLY).And retail traders should know.We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.So how do we know what these investors just did? Today, Benzinga's options scanner spotted 56 ...
Where Will LLY Be in 5 Years?
Yahoo Finance· 2025-10-07 13:33
Core Insights - Eli Lilly's share prices experienced significant growth in 2023 and 2024 due to excitement over GLP-1 diabetes and weight loss therapies, but have since stabilized between $700 and $900 since mid-2024 [2][9] - Valuation concerns, with a forward P/E ratio of around 27, have contributed to the stock's performance, especially when compared to Novo Nordisk's P/E of 14 [3] - Despite current valuation concerns, there is potential for the stock to catch up over the next five years [4] Revenue and Growth Drivers - Lilly's GLP-1 medication, tirzepatide, has been a key revenue driver, generating $5.3 billion in 2023 and projected to reach $16.5 billion in 2024 [6] - Sales for tirzepatide in the first half of 2025 totaled $14.7 billion, with forecasts predicting annual sales to exceed $62 billion in five years [7] - The company is also developing orforglipron, a promising obesity treatment, expected to generate $12.7 billion in annual sales by 2030 [8] Future Outlook - The stock price has remained stable, but sales from diabetes and obesity treatments are anticipated to grow rapidly [9] - While the premium valuation may decrease, further earnings growth could lead to substantial returns over the next five years [9]
Market Snapshot: Mining Financing, Pharma Milestones, and ECB Sentiment
Stock Market News· 2025-10-07 11:08
Key TakeawaysTitan Mining Corporation (TI) has received financing interest of up to $120 million from the US EXIM Bank for its Kilbourne Graphite Project, signaling significant government support for critical mineral development.Eli Lilly and Co (LLY) announced that its drug Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to demonstrate four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis, with 80% of patients maintaining long-term remission.Ec ...
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Prnewswire· 2025-10-07 10:45
Approximately 80% of Omvoh-treated patients in the LUCENT-3 study who achieved clinical remission at one year maintained long-term, corticosteroid-free clinical and endoscopic remission At four years, nearly all patients who achieved clinical remission at one year had improvements in bowel urgency, one of the most disruptive symptoms for patients , /PRNewswire/ -- New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 (IL-23p19) to help patien ...
BL Morning report: October 7, 2025
BusinessLine· 2025-10-07 01:00
Group 1: WeWork IPO - WeWork India's IPO has seen a muted demand with only 13% subscription on the second day [1] - The IPO is priced between ₹615 and ₹648 per share and is entirely an offer for sale, with no proceeds going to the company [1] - Anchor investors have committed ₹1,348 crore ahead of the IPO, but brokerages express caution due to high valuations and fixed costs despite the strong brand and profitability [1] Group 2: Eli Lilly Investment - Eli Lilly and Company plans to invest over $1 billion in a new contract manufacturing facility in Hyderabad, India [2] - The new hub will enhance Lilly's manufacturing network with advanced technical and quality capabilities, and hiring has already begun [2] - This investment reflects Lilly's global expansion strategy and confidence in India's talent and infrastructure, with over $55 billion committed to global facilities since 2020 [2] Group 3: Cough Syrup Investigation - A Special Investigation Team (SIT) has been formed to investigate the deaths of 14 children in Chhindwara, linked to a toxic cough syrup [3] - The cough syrup, manufactured in Tamil Nadu, has been banned by the state, and a wider investigation is underway [3] - The syrup was found to contain diethylene glycol, prompting nationwide scrutiny of similar drugs [3]
Eli Lilly to inject $1 billion in contract manufacturing operations in India
The Times Of India· 2025-10-07 00:22
Core Insights - Eli Lilly and Company is investing over $1 billion (approximately ₹8,900 crore) to establish new contract manufacturing facilities in India, marking one of the largest investments in the Indian pharma sector in recent years [3] - The investment decision was influenced by Telangana's favorable ecosystem, including skilled manpower, infrastructure, and government support, despite competition from other states [1][3] - The new hub in Hyderabad will enhance Eli Lilly's manufacturing and supply capabilities, supporting its evolving portfolio and leveraging India's talent pool [1][3] Investment and Expansion - Since 2020, Eli Lilly has committed over $55 billion globally to build, expand, and acquire facilities [2][3] - The new facilities will focus on developing and manufacturing medicines for conditions such as diabetes, obesity, Alzheimer's disease, cancer, and autoimmune diseases [2][3] - The company plans to begin immediate recruitment for various roles at the new hub, including engineers, chemists, and quality control professionals [2][3] Job Creation and Local Impact - The investment will not only expand Eli Lilly's manufacturing and global medicine supply capacity in Hyderabad but also create job opportunities for local youth [2][3] - The Telangana government confirmed that all investments will be made entirely within the state [2][3]
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
MarketBeat· 2025-10-06 23:35
Core Viewpoint - Eli Lilly and Company has experienced a significant stock recovery after a sharp decline in August, driven by developments related to tariff negotiations and its strong product performance in the weight loss and diabetes drug market [1][2]. Stock Performance - Eli Lilly's stock surged by 16% during the trading week ending October 3, reaching its highest level since April [1]. - Following a 14% drop on August 7, the stock has increased over 31% year-to-date, with approximately half of this gain occurring recently [2]. Tariff Developments - President Trump announced a 100% tariff on imported branded pharmaceuticals on September 25, but companies investing in U.S. manufacturing would be exempt [3]. - Clarity emerged on September 30 and October 1 when Pfizer announced a deal with the Trump administration, leading to a significant rise in Eli Lilly's shares as it was anticipated that Lilly could secure a similar arrangement [4][5]. Strategic Positioning - Eli Lilly has proactively prepared for potential tariffs by announcing a $27 billion increase in U.S. manufacturing investments and plans to become a net exporter of injectable GLP-1s [6]. - The company is well-positioned to negotiate a tariff-avoiding deal, which has contributed to the recent rise in its stock price [6]. Market Impact - A potential deal similar to Pfizer's could lead to a significant reduction in U.S. drug prices, which may impact revenues, but the concessions are primarily in smaller market segments [7][8]. - Medicaid's spending on Eli Lilly's key drugs, Zepbound and Mounjaro, is relatively low, suggesting that pricing concessions in this area would have minimal impact on overall sales [9]. Future Outlook - The consensus price target for Eli Lilly is approximately $933, indicating an 11% potential upside, with the possibility of further stock price increases if a deal is secured [10].
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know
ZACKS· 2025-10-06 19:01
Key Takeaways Lilly stock surged 16% last week amid optimism following Pfizer's federal agreement announcement.The Pfizer deal eased investor concerns over drug pricing and tariffs in the pharma sector.Lilly's $27B U.S. expansion aims to boost production of Mounjaro and Zepbound medicines.Shares of Eli Lilly (LLY) have surged 16% in the past week, driven primarily by positive investor expectations around the broader pharmaceutical sector after Pfizer (PFE) announced a landmark agreement with the Trump admin ...